• The primary series with ActHIB, MenHibrix, Hiberox, or Pentacel consists of 3 doses and should be administered at ages 2, 4, and 6 months. The primary series with PediaVaxHib consists of 2 doses and should be administered at ages 2 and 4 months; a dose at age 6 months is not indicated.
• One booster dose (dose 2 or 4, depending on vaccine used in primary series) of Hib vaccine should be administered at age 12 through 15 months.
• For recommendations on the use of MenHibrix in patients at increased risk for meningococcal disease, refer to the meningococcal vaccine footnotes and also MMWR 2014;63(RR01):1–13, available at www.cdc.gov/mmwr/pdf/rr/rr6301.pdf.

Catch-up vaccination:
• If dose 1 was administered at ages 12 through 14 months, administer a second (final) dose at least 8 weeks after dose 1, regardless of Hib vaccine used in the primary series.
• If both doses were PRP-DMP (PediaVaxHib or Convax) and were administered before the first birthday, the third (and final) dose should be administered at age 12 through 59 months and at least 8 weeks after second dose.
• If the first dose was administered at age 7 through 11 months, administer the second dose at least 4 weeks later and a third (and final) dose at age 12 through 15 months or 8 weeks after the second dose, whichever is later.
• If first dose was administered before the first birthday and second dose administered at younger than 15 months, a third (and final) dose should be administered 8 weeks later.
• For unvaccinated children ages 15 through 59 months, administer only 1 dose.
• For other catch-up guidance, see Figure 2. For catch-up guidance related to MenHibrix, see the meningococcal vaccine footnotes and also MMWR 2014;63(RR01):1–13, available at www.cdc.gov/mmwr/pdf/rr/rr6301.pdf.

Vaccination of persons with high-risk conditions:
• Children ages 12 through 59 months who are at increased risk for Hib disease, including chemotherapy recipients and those with anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV) infection, immunoglobulin deficiency, or early component complement deficiency, who have received either no doses or only 1 dose of Hib vaccine before age 12 months, should receive 2 additional doses of Hib vaccine, 8 weeks apart; children who received 2 or more doses of Hib vaccine before age 12 months should receive 1 additional dose.
• For patients younger than age 5 years undergoing chemotherapy or radiation treatment who received a Hib vaccine dose(s) within 14 days of starting therapy or during therapy, repeat the dose(s) at least 3 months following therapy completion.
• Recipients of hematopoietic cell transplant (HCT) should be revaccinated with a 3-dose regimen of Hib vaccine starting 8 to 12 months after successful transplant, regardless of vaccination history; doses should be administered at least 4 weeks apart.
• A single dose of any Hib-containing vaccine should be administered to unimmunized* children and adolescents age 15 months and older undergoing an elective splenectomy; if possible, Hib vaccine should be administered at least 14 days before procedure.
• Hib vaccine is not routinely recommended for patients ages 5 years or older. However, 1 dose of Hib vaccine should be administered to unimmunized* persons ages 5 years or older who have anatomic or functional asplenia (including sickle cell disease) and unimmunized* persons ages 5 through 18 years with HIV infection.*Patients who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after age 14 months are considered unimmunized.

5. Pneumococcal vaccines. (Minimum age: 6 weeks for PCV13, 2 years for PPSV23)

Routine vaccination with PCV13:
• Administer a 4-dose series of PCV13 vaccine at ages 2, 4, and 6 months and at age 12 through 15 months.

Catch-up vaccination with PCV13:
• Administer 1 dose of PCV13 to all healthy children ages 24 through 59 months who are not completely vaccinated for their age.
• For other catch-up guidance, see Figure 2.

Vaccination of persons with high-risk conditions with PCV13 and PPSV23:
• All recommended PCV13 doses should be administered prior to PPSV23 vaccination if possible.
• For children ages 2 through 5 years with any of the following conditions: chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus, alcoholism, or chronic liver disease, who have not received PPSV23, administer 1 dose of PPSV23. If PCV13 has been received previously, then PPSV23 should be administered at least 8 weeks after any prior PCV13 dose.
• A single revaccination with PPSV23 should be administered 5 years after the first dose to children with sickle cell disease or other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; generalized malignancy; solid organ transplantation; or multiple myeloma.
• For children ages 18 through 18 years with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure), chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus, alcoholism, or chronic liver disease, who have not received PPSV23, administer 1 dose of PPSV23. If PCV13 has been received previously, then PPSV23 should be administered at least 8 weeks after any prior PCV13 dose.

6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)

Routine vaccination:
• Administer a 4-dose series of IPV at ages 2, 4, 6 through 18 months, and 4 through 6 years. The final dose in the series should be administered on or after the fourth birthday and at least 6 months after the previous dose.

Catch-up vaccination:
• In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk of imminent exposure to circulating poliovirus (i.e., travel to a polio-endemic region or during an outbreak).
• If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 through 6 years and at least 6 months after the previous dose.
• A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.
• If both oral polio vaccine (OPV) and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age. If only OPV was administered, and all doses were given prior to age 4 years, 1 dose of IPV should be given at age 4 years or older, and at least 4 weeks after the last OPV dose.
• IPV is not routinely recommended for U.S. residents ages 18 years or older.
• For other catch-up guidance, see Figure 2.

7. Influenza vaccines. (Minimum age: 6 months for inactivated influenza vaccine [IIV], 18 years for recombinant influenza vaccine [RIV])

Routine vaccination:
• Administer influenza vaccine annually to all children beginning at age 6 months. For the 2016–17 season, use of live attenuated influenza vaccine (LAIV) is not recommended.

For children ages 6 months through 8 years:
• For the 2016–17 season, administer 2 doses (separated by at least 4 weeks) to children who are receiving influenza vaccine for the first time or who have not previously received 2 doses of trivalent or quadrivalent influenza vaccine before July 1, 2016. For additional guidance, follow dosing guidelines in the 2016–17 ACIP influenza vaccine recommendations (see MMWR 2016;65(5):1–54, available at www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6505.pdf.).
• For the 2017–18 season, follow dosing guidelines in the 2017–18 ACIP influenza vaccine recommendations.

For persons ages 9 years and older:
• Administer 1 dose.

8. Measles, mumps, and rubella (MMR) vaccine. (Minimum age: 12 months for routine vaccination)

Routine vaccination:
• Administer a 2-dose series of MMR vaccine at ages 12 through 15 months and 4 through 6 years. The second dose may be administered before age 4 years, provided at least 4 weeks have elapsed since the first dose.
• Administer 1 dose of MMR vaccine to infants ages 6 through 11 months before departure from the United States for international travel. These children should be revaccinated with 2 doses of MMR vaccine, the first at age 12 through 15 months (if the child remains in an area where disease risk is high), and the second dose at least 4 weeks later.
• Administer 2 doses of MMR vaccine to children ages 12 months and older before departure from the United States for international travel. The first dose should be administered on or after age 12 months and the second dose at least 4 weeks later.

Catch-up vaccination:
• Ensure that all school-aged children and adolescents have had 2 doses of MMR vaccine; the minimum interval between the 2 doses is 4 weeks.

9. Varicella (VAR) vaccine. (Minimum age: 12 months)

Routine vaccination:
• Administer a 2-dose series of VAR vaccine at ages 12 through 15 months and 4 through 6 years. The second dose may be administered before age 4 years, provided at least 3 months have elapsed since the first dose. If the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid.

Catch-up vaccination:
• Ensure that all persons ages 7 through 18 years without evidence of immunity (see MMWR 2007;56[No. RR-4], available at www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 doses of varicella vaccine. For children ages 7 through 12 years, the recommended minimum interval between doses is 3 months (if the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid); for persons ages 13 years and older, the minimum interval between doses is 4 weeks.

10. Hepatitis A (HepA) vaccine. (Minimum age: 12 months)

Routine vaccination:
• Initiate the 2-dose HepA vaccine series at ages 12 through 23 months; separate the 2 doses by 6 to 18 months.
• Children who have received 1 dose of HepA vaccine before age 24 months should receive a second dose 6 to 18 months after the first dose.